![](https://investorshub.advfn.com/uicon/423925.png?cb=1539163194)
Monday, April 05, 2021 12:42:38 PM
D- Please replace the sticky with this one. TIA, G
UPDATED: SEE BELOW
Direct link to "All in 1"; includes all documents below; 139 pages
401: INTERVENOR EPADI II’S MOTION TO INTERVENE PURSUANT TO FED. R. CIV. P. 24, ORAL ARGUMENT REQUESTED TELEPHONICALLY OR VIA ZOOM
401-1: INDEX OF EXHIBITS
401-2: Exhibit A: Email from Avi Silberberg, Esq. to Amarin’s CEO, John Thero, requesting that Amarin seek Rule 60 relief, dated November 9, 2020 (Sender and Reciept’s email addresses have been redacted)
401-3: Exhibit B: Yahoo Finance screenshot showing the collapse of Amarin’s stock price in the immediate aftermath of the Judgment, dated March 31, 2020
401-4: Exhibit C: True Excerpts from the Amicus Brief filed by the Aimed Alliance in support of Amarin’s Petition for Certiorari to the United States Supreme Court, dated March 4,2021
401-5: DECLARATION OF MICHAEL S. KASANOFF IN SUPPORT OF EPADI II’S MOTION TO INZERVENE PURSUANT TO FED. R. CIV. P. 24
401-6: CERTIFICATE OF SERVICE
405: INTERVENOR EPADI II’S MOTION TO VACATE JUDGMENT PURSUANT TO FED. R. CIV. P.
ORAL ARGUMENT REQUESTED TELEPHONICALLY OR VIA ZOOM
405-1: INDEX OF EXHIBITS
405-2: Exhibit A: Expert Report prepared by Dr. Gavin E. Jarvis, dated March 12, 2021
405-3: Exhibit B: Dr. Jarvis’s Curriculum Vitae
405-4: Exhibit C: Curfman, G., Bhatt, D.L. & Pencina, M., Federal Judge Invalidates Icosapent Ethyl Patents But Based on a Common Statistical Mistake, Nat. Biotehcnol 38, 939-941(2020)
405-5: Exhibit D: Abstract of the Paper supporting Curfman, G., Bhatt, D.L. & Pencina, M., Federal Judge Invalidates Icosapent Ethyl Patents But Based on a Common Statistical Mistake, Nat. Biotehcnol 38, 939-941(2020)
405-6: Exhibit E: Paper supporting Curfman, G., Bhatt, D.L. & Pencina, M., Federal Judge Invalidates Icosapent Ethyl Patents But Based on a Common Statistical Mistake, Nat. Biotehcnol 38, 939-941(2020)
405-7: Exhibit F: Kurabayashi et. al., Eicosapentaenoic acid effect on hyperlipedema in menopausal Japanese women. Obster Gynecol, 2000;96(4):521-8
405-8: DECLARATION OF MICHAEL S. KASANOFF IN SUPPORT OF EPADI II’S MOTION TO VACATE JUDGMENT PURSUANT TO FED. R. CIV. P. 24
405-9: CERTIFICATE OF SERVICE
407: VERIFIED PETITION FOR PERMISSION TO PRACTICE IN THIS CASE ONLY BY ATTORNEY NOT ADMITTED TO THE BAR OF THIS COURT AND DESIGNATION OF LOCAL COUNSEL
408: PLAINTIFFS’ RESPONSE TO MOTIONS OF PROPOSED INTERVENOR EPA DRUG INITIATIVE II (ECF NOS. 401 AND 405)
409: DEFENDANTS’ RESPONSE TO THE MOTION TO INTERVENE PURSUANT TO FED. R. CIV. P. 24 BY “EPADI II”
Best,
G
Disclosure: I wrote this post myself, and it expresses my own opinions (IMHO). I am not receiving compensation for it.
Notice: This post is not investment advice, and not a recommendation to neither buy nor hold nor sell.
Recent AMRN News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 11:30:10 AM
- Amarin Board of Directors Announces CEO Transition • GlobeNewswire Inc. • 06/04/2024 11:30:00 AM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A. • GlobeNewswire Inc. • 05/28/2024 12:15:23 PM
- Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Amarin Reports First Quarter 2024 Business Update and Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • PR Newswire (Canada) • 04/08/2024 10:30:00 AM
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • GlobeNewswire Inc. • 04/06/2024 07:30:00 PM
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/04/2024 10:30:53 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/04/2024 01:00:24 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 12:06:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 12:05:56 PM
- Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 12:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024 • GlobeNewswire Inc. • 02/15/2024 01:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/12/2024 01:00:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:31:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:22 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM